Robotic radical cystectomy: Medium-term oncologic follow-up

METHODS: 275 patients have undergone RARC and urinary diversion at two institutions for bladder cancer between 2005-present. We performed a retrospective analysis of the 139 patients who underwent RARC with a minimum of 2 years follow-up. Medium term oncologic outcomes including recurrence rates, time to recurrence, recurrence-free survival (RFS), disease-specific survival (DSS) were analyzed. Follow-up was measured from time of surgery to time of most recent clinical follow-up.